| |
| |
|
| Insider
Information: |
Korenberg Matthew E |
| Relationship: |
PRESIDENT & CHIEF OPER... |
| City: |
La Jolla |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
103,861 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$7,258,845 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
103,861 |
|
|
| Total
Value |
$7,258,845 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
PRESIDENT & CHIEF OPER... |
2024-02-27 |
103,861 |
2015-08-06 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
PRESIDENT & CHIEF OPERATING |
• – – |
2024-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
14,416 |
103,861 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
PRESIDENT & CHIEF OPERATING |
• – – |
2024-02-15 |
4 |
D |
$74.65 |
$356,678 |
D/D |
(4,778) |
89,445 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
PRESIDENT & CHIEF OPERATING |
• – – |
2024-01-02 |
4 |
D |
$72.31 |
$210,928 |
D/D |
(2,917) |
94,223 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
PRESIDENT & CHIEF OPERATING |
• – – |
2023-12-05 |
4 |
D |
$59.61 |
$118,266 |
D/D |
(1,984) |
97,140 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
PRESIDENT & CHIEF OPERATING |
• – – |
2023-06-30 |
4 |
A |
$56.78 |
$21,349 |
D/D |
376 |
99,124 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & COO |
• – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
9,069 |
98,748 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & COO |
• – – |
2023-02-15 |
4 |
D |
$72.98 |
$210,912 |
D/D |
(2,890) |
89,679 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & COO |
• – – |
2022-12-28 |
4 |
D |
$66.29 |
$255,813 |
D/D |
(3,859) |
92,569 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & COO |
• – – |
2022-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
96,428 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & COO |
• – – |
2022-11-30 |
4 |
D |
$72.90 |
$261,930 |
D/D |
(3,593) |
82,428 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & COO |
• – – |
2022-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
27,714 |
86,021 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2022-06-30 |
4 |
A |
$75.84 |
$12,437 |
D/D |
164 |
52,532 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2022-02-15 |
4 |
D |
$123.68 |
$421,378 |
D/D |
(3,407) |
44,306 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2022-01-26 |
4 |
D |
$113.68 |
$412,431 |
D/D |
(3,628) |
47,713 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
11,651 |
51,341 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2021-06-30 |
4 |
A |
$85.91 |
$21,220 |
D/D |
247 |
39,690 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2021-02-15 |
4 |
D |
$172.46 |
$398,210 |
D/D |
(2,309) |
39,443 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,819 |
41,752 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2021-01-25 |
4 |
D |
$156.01 |
$329,337 |
D/D |
(2,111) |
30,933 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2021-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
7,108 |
32,373 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2020-06-30 |
4 |
A |
$89.03 |
$21,189 |
D/D |
238 |
25,936 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2020-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
6,848 |
26,864 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2019-12-20 |
4 |
D |
$105.87 |
$223,809 |
D/D |
(2,114) |
20,016 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2019-12-20 |
4 |
A |
$0.00 |
$0 |
D/D |
4,979 |
20,995 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2019-09-03 |
4 |
B |
$86.18 |
$43,091 |
D/D |
500 |
17,151 |
2.74 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
